계명대학교 의학도서관 Repository

The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial

Metadata Downloads
Author(s)
Young-Rak ChoYoung-Dae KimTae-Ho ParkKyungil ParkJong-Sung ParkHeekyung BaekSun-Young ChoiKee-Sik KimTaek-Jong HongTae-Hyun YangJin-Yong HwangJong-Seon ParkSeung-Ho HurSang-Gon Lee
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
Trials
Issued Date
2011
Volume
12
Issue
1
Keyword
ValsartanMyocardial Infarction
Abstract
Background: Angiotensin-converting enzyme inhibitors and the angiotensin-receptor blocker valsartan ameliorate
ventricular remodeling after myocardial infarction (MI). Based on previous clinical trials, a maximum clinical dose is
recommended in practical guidelines. Yet, has not been clearly demonstrated whether the recommended dose is
more efficacious compared to the lower dose that is commonly used in clinical practice.
Method/Design: Valsartan in post-MI remodeling (VALID) is a randomized, open-label, single-blinded multicenter
study designed to compare the efficacy of different clinical dose of valsartan on the post-MI ventricular
remodeling. This study also aims to assess neurohormone change and clinical parameters of patients during the
post-infarct period. A total of 1116 patients with left ventricular dysfunction following the first episode of acute ST-
elevation MI are to be enrolled and randomized to a maximal tolerable dose (up to 320 mg/day) or usual dose (80
mg/day) of valsartan for 12 months in 2:1 ratio. Echocardiographic analysis for quantifying post-MI ventricular
remodeling is to be conducted in central core laboratory. Clinical assessment and laboratory test are performed at
fixed times.
Discussion: VALID is a multicenter collaborative study to evaluate the impact of dose of valsartan on the post-MI
ventricular remodeling. The results of the study provide information about optimal dosing of the drug in the
management of patients after MI. The results will be available by 2012.
Trial registration: NCT01340326
Keywords: Valsartan, Myocardial Infarction
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Young-Rak Cho et al. (2011). The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial
infarction ventricular remodeling: study protocol for a randomized controlled trial. Trials, 12(1), 247–247. doi: 10.1186/1745-6215-12-247
Type
Article
ISSN
1745-6215
DOI
10.1186/1745-6215-12-247
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34774
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.